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In this issue of the Journal, Strüber and associates1 report the results of aseries of experiments comparing the effect of retrograde versus antegradeperfusion of lung grafts on oxygenation, compliance, and surfactant func-tion in a porcine model. The Hannover group has a venerable track recordof conducting innovative research in lung preservation and was the first toreport the use of exogenous surfactant therapy to treat ischemia-reperfusion
injury after clinical lung transplantation.2 The current article will add to the bur-
geoning field of research on new methods of lung preservation designed to decrease
post-transplant graft dysfunction and potentially enlarge the donor pool. 
Lung Preservation as a Rate-limiting Step to Lung Transplantation
A shortage of suitable lung grafts has been a major rate-limiting step in clinical lung
transplantation during the past decade. The majority of prospective donor lungs
exhibit hypoxemia and pulmonary infiltrates due to edema, aspiration, and pneu-
monia associated with the effects of brain death and the need for ventilatory support
in organ donors.3 Recent work has confirmed that some lung grafts previously
deemed unsuitable can in fact be transplanted successfully.4 Nevertheless, most
such grafts will still be too compromised to permit successful harvesting for trans-
plantation. New methods to rescue these grafts or mitigate ischemia-reperfusion
injury after transplantation will go a long way toward reducing the supply-demand
imbalance that currently plagues clinical lung transplantation. 
Pulmonary Surfactant and Lung Preservation
An interesting feature of Strüber and associates’ article is a study of the impact of
different techniques of lung graft flushing on the pulmonary surfactant system.
Surfactant is a lipid-protein complex produced by type II pneumocytes, which sta-
bilizes the lung by reducing surface tension at the alveolar-pulmonary capillary
interface.5 Surfactant recovered by bronchoalveolar lavage consists of subfractions
differing in morphologic appearance and buoyant density. The heavy subtype or
surfactant large aggregate fraction, which contains lamellar bodies, tubular myelin,
and large vesicles, is rich in the surfactant proteins SP-A, SP-B, and SP-C and is
highly surface active. The light subtype or small aggregate subfraction, consisting
of small vesicles, contains less surfactant protein and has poor surface activity.5,6 In
1991, my colleagues and I5 reviewed the laboratory work that was performed
between 1965 and 1974 characterizing alterations in the surface activity of surfac-
tant after lung reimplantation and allografting in dogs. Our laboratory subsequently
reported that lung transplantation in dogs after a 12-hour period of cold ischemia
and a 6-hour period of reperfusion was associated with increased total serum pro-
tein in lung lavage, an increased small aggregate/large aggregate (SA/LA) ratio,
increased sphingomyelin, and decreased phosphatidylglycerol concentrations in
large aggregates and a decreased SP-A content.7 These alterations in surfactant
resembled those observed in many injuries resembling adult respiratory distress
syndrome.8 Further studies in rats supported these findings9,10; the latter study cor-
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related the severity of ischemia-reperfusion injury with the
amount of tubular myelin in the lungs on stereologic analy-
sis.10 The Hannover group confirmed in 1998 that pul-
monary surfactant activity was impaired clinically in lung
transplant recipients.11 Further experimental work by
Strüber and his associates12 showed that lung flushing with
low-potassium dextran (LPD) solution was associated with
a lower SA/LA ratio and better surfactant function than
Euro-Collins solution in a porcine model of 90 minutes of
warm ischemia. 
Retrograde Versus Antegrade Lung Flushing for
Preservation
In the article in this month’s Journal, the Hannover group
focused on whether the use of retrograde, as opposed to
antegrade, lung flushing with LPD solution would produce
better oxygenation, lung compliance, and surfactant func-
tion after 24 hours of cold ischemia. Administration of pul-
monary flush solution via the retrograde route has been
explored since the early 1990s as an alternative technique to
overcome some of the limitations associated with antegrade
flushing methods.13-18 One of the postulated advantages of
the retrograde technique includes a lower vascular resis-
tance during flushing on the pulmonary venous as opposed
to the pulmonary arterial side. In addition, it has been pro-
posed that flush solutions delivered retrogradely through
the left atrium could perfuse both the bronchial and pul-
monary circulations, thus theoretically enhancing pul-
monary parenchymal and airway preservation13;
subsequent work, however, has cast doubt on this hypothe-
sis.17 In the current article, Strüber and associates showed
that retrograde flushing with LPD solution resulted in sig-
nificantly better oxygenation and compliance in trans-
planted lungs than antegrade flushing. However, the results
with respect to surfactant function and aggregate forms
were equivocal. Unfortunately, the second and final bron-
choalveolar lavage for surfactant analysis was carried out
after only 2 hours of reperfusion, whereas its performance
at the end of the experiment (ie, after 7 hours of reperfu-
sion) would have produced more meaningful results.
Furthermore, the measurement of levels of SP-A in bron-
choalveolar lavage samples would have significantly
strengthened this article, since lung preservation is associ-
ated with decreased SP-A levels in other models.7 The
authors did show, however, that retrograde lung flushing
was associated with a significantly lower SA/LA ratio at 2
hours of reperfusion than antegrade flushing, although sur-
face tension in the antegrade and retrograde groups
increased to a similar degree. They concluded that although
retrograde lung flushing led to better initial graft function
than the standard antegrade perfusion technique, surfactant
dysfunction was present in both groups. This latter finding
was consistent with the results of studies by Chen and asso-
ciates,15 who demonstrated that the contents of lamellar
bodies of type II pneumocytes (that contain surfactant) were
reduced after retrograde flushing, despite excellent preser-
vation of oxygenation and lung compliance after 24 hours
of preservation. 
Possible Role of Exogenous Surfactant Therapy in
Lung Preservation
The observation that lung preservation results in adverse
alterations in the endogenous surfactant system resulted in
our suggestion in 1991 that exogenous surfactant therapy be
explored as a “future tool of the lung transplant surgeon.”5
Exogenous surfactant therapy has been investigated for
some time as a possible treatment of various types of severe
acute lung injury.8 Key issues that need to be considered in
the potential application of this treatment modality include
the type of exogenous surfactant used, its delivery tech-
nique (ie, instilled versus aerosolized), and the timing of its
administration (ie, to donors, recipients, or both).
Furthermore, ventilatory strategies subsequent to its admin-
istration could have a profound impact on both the endoge-
nous and exogenous surfactant pools.6,19
Work in our laboratory in 1996 showed that in normal
canine lungs treatment of donors with exogenous surfactant
before hypothermic graft storage for 36 hours was associ-
ated with less severe lung injury after reperfusion than
recipient therapy alone.20 Furthermore, combined donor
aerosol and recipient instilled surfactant therapy was asso-
ciated with a superior physiologic response during reperfu-
sion and an increased recovery of aerosolized and instilled
exogenous surfactant, compared with either modality of
exogenous surfactant treatment alone. In a subsequent
study, a canine model of the compromised lung donor was
created via 8 hours of high-volume ventilation.21
Administration of instilled bovine lipid extract surfactant to
donor lungs in this model reduced protein leak, maintained
a low surfactant SA/LA ratio, and resulted in better oxy-
genation after transplantation than that of untreated grafts.21
Further experimental work has shown that the exogenous
instilled surfactant did not equilibrate completely with the
endogenous surfactant pool in this model, despite being in
the transplanted lungs for 30 hours.6
Experience with exogenous surfactant therapy in the set-
ting of clinical lung transplantation has, to date, been lim-
ited. To our knowledge, no clinical report on the
administration of exogenous surfactant to lung donors has
been published. Strüber and associates2 were the first to
document the successful clinical treatment of a lung trans-
plant recipient with established ischemia-reperfusion injury
with nebulized synthetic surfactant in 1995. Subsequent
review of their clinical experience with graft dysfunction
after lung transplantation demonstrated the successful treat-
ment of 6 consecutive patients with severe ischemia-reper-
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fusion injury with the same nebulized exogenous surfactant
preparation.22 The ability of the chosen therapy to consis-
tently mitigate ischemia-reperfusion injury was surprising,
because the surfactant preparation lacked SP-A, which has
been shown experimentally to be important in resisting
inhibition of surfactant by serum protein in the airways.5,23
Moreover, nebulized exogenous surfactant would have been
expected to localize in better ventilated (ie, less injured)
areas of the lungs, rather than in those with suboptimal ven-
tilation resulting from ongoing ischemia-reperfusion injury. 
Summary
The above experiences indicate that exogenous surfactant
therapy is a potentially promising therapy to mitigate severe
pulmonary ischemia-reperfusion injury, but more research
needs to be done to determine the optimal surfactant prepa-
ration and mode of therapy in the clinical setting. In addi-
tion, the time has come to formally evaluate retrograde
versus antegrade flushing techniques in clinical lung trans-
plantation. This requires an appropriately powered (likely
multi-institutional) randomized controlled trial, with well-
defined, a priori, primary and secondary end points.
Furthermore, the ability of exogenous surfactant therapy,
retrograde lung flushing, and other new techniques to res-
cue donor lung grafts that have been subject to various
forms of experimentally induced injury should be studied
further in the laboratory to determine the potential future
use of these treatment modalities in the clinical arena to
expand the pool of donor lungs.
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